Therefore, with the advantages of the molecular classifiers BCL2A1 and AIM2, we identified a small proportion of pN0 patients (17.6%, 19/108) at high risk of tumor progression and poor outcomes, a subset that was imperceptible by conventional pT or G stratification (Figure S3A). This evidence concerns the gene BCL2A1 and neoplasm.